Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tempol Hydroxylamine SCHEMBL23902 | 0.79 | GAA (0.56) | GAAL3MBTL1 | |
| SCHEMBL11138605 | 0.79 | GAA (0.30) | GAAL3MBTL1 | |
| SCHEMBL4801721 | 0.79 | GAA (0.43) | GAAL3MBTL1 | |
| SCHEMBL11140946 | 0.78 | KMT2A (0.34) | — | |
| SCHEMBL4802283 | 0.78 | — | — | |
| Tempol Hydroxylamine SCHEMBL987556 | 0.77 | GAA (0.54) | GAAL3MBTL1 | |
| SCHEMBL6827362 | 0.76 | — | — | |
| SCHEMBL14450633 | 0.74 | GAA (0.36) | GAAL3MBTL1 | |
| SCHEMBL16349255 | 0.74 | GAA (0.37) | GAAL3MBTL1 | |
| SCHEMBL6284229 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787959-B2 | Radiation curable gravure ink | CHANGZHOU GREEN PHOTOSENSITIVE MATERIALS CO., LTD. (CN) | 2023-10-17 | — | — | US | disclosed |
| US-20210115276-A1 | Radiation curable Gravure Ink | CHANGZHOU GREEN PHOTOSENSITIVE MAT CO LTD (CN) | 2021-04-22 | — | — | US | disclosed |
| US-7402639-B2 | 1-alkoxy-polyalkyl-piperidine derivatives and their use as polymerization regulators | CIBA SPECIALTY CHEMICALS CORP. (US) | 2008-07-22 | — | — | US | disclosed |
| US-20070225397-A1 | In-Can Stabilizers | CIBA SPECIALTY CHEMICALS CORP. | 2007-09-27 | — | — | US | disclosed |
| US-6927295-B2 | A polymerization catalyst for free radical polymerization of ethylenically unsaturated monomers | CIBA SPECIALTY CHEMICALS CORP. (US) | 2005-08-09 | — | — | US | disclosed |
| US-20050131177-A1 | 1-Alkoxy-polyalkyl-piperidine derivatives and their use as polymerization regulators | KRAMER ANDREAS (SE) | 2005-06-16 | — | — | US | disclosed |
| US-6683142-B2 | PROVIDE POLYMERIC RESIN PRODUCTS HAVING LOW POLYDISPERSITY. | CIBA SPECIALTY CHEMICALS CORPORATION | 2004-01-27 | — | — | US | disclosed |
| US-20030220423-A1 | 1-alkoxy-polyalkyl-piperidine derivatives and their use as polymerization regulators | KRAMER ANDREAS (CH) | 2003-11-27 | — | — | US | disclosed |
| US-20020107397-A1 | 1-alkoxy-polyalkyl-piperidine derivatives and their use as polymerization regulators | KRAMER ANDREAS (CH) | 2002-08-08 | — | — | US | disclosed |
| US-6353107-B1 | FREE RADICAL CATALYSTS FOR ADDITION POLYMERIZATION; NARROW MOLECULAR WEIGHT DISTRIBUTION; HIGH PURITY AND COLORLESS | CIBA SPECIALTY CHEMICALS CORPORATION | 2002-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131177-A1 | 1-Alkoxy-polyalkyl-piperidine derivatives and their use as polymerization regulators | PYM1, PTGER1, CBR1 | GAA 3127/4885L3MBTL1 1097/4885 |
| US-20020107397-A1 | 1-alkoxy-polyalkyl-piperidine derivatives and their use as polymerization regulators | CBR1, PYM1, ELOC | GAA 2233/4885L3MBTL1 2453/4885 |
| US-20030220423-A1 | 1-alkoxy-polyalkyl-piperidine derivatives and their use as polymerization regulators | PYM1, ELOC, CBR1 | GAA 2416/4885L3MBTL1 2570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.